Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”

Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0166

View: 548 Download: 27

The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0152

View: 411 Download: 10 Crossref: 1

Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e180-e182. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0125

View: 468 Download: 20

Original Article

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 2931 Download: 265 Crossref: 5

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987

View: 2616 Download: 419 Crossref: 12

Review

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim

Clin Mol Hepatol. 2025;31(1):74-89. Published online October 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0631

View: 3424 Download: 360 Web of Science: 7 Crossref: 10

Letter to the Editor

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 1663 Download: 65 Web of Science: 1 Crossref: 1

Original Article

Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023

Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):756-770. Published online June 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0318

View: 2447 Download: 106 Web of Science: 6 Crossref: 7

Review

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0239

View: 10241 Download: 375 Web of Science: 32 Crossref: 38

Original Article

Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang

Received February 12, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0169 [Accepted]

View: 539 Download: 40

1 |

Viewed By 8901	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7633	MAFLD: How is it different from NAFLD?
Viewed By 5508	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5119	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4595	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 293	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 204	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search